Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

15 Apr 2021

Abstract excerpt

BBIBP-CorV and ZF2001 are two COVID-19 vaccines developed in China. BBIBP-CorV is an inactivated virus vaccine approved for conditional marketing authorisation1 and ZF2001 is a recombinant dimeric receptor-binding domain (RBD) protein vaccine currently in phase 3 clinical trials and approved for emergency use in China and Uzbekistan.2,3 Both vaccines showed good immunogenicity in phase 1 and 2 trials.1,3

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33870240
DOI: 10.1016/s2666-5247(21)00082-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 14 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2PMID 33870240Read ↗

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccinesSemantic proximity Read ↗

Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccineSemantic proximity Read ↗

Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity Read ↗

Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and UtilitySemantic proximity Read ↗

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 VaccineesSemantic proximity Read ↗

Anti-SARS-Cov-2 S-RBD IgG formed after BNT162b2 vaccination can bind C1q and activate complementSemantic proximity Read ↗

Safety and Efficacy of the FAKHRAVAC Compared with BBIBP-Corv2 Against SARS-CoV-2 in Adults: A Non-Inferiority Multi-Center TrialSemantic proximity Read ↗

Immunogenicity following two doses of BBIBP-CorV vaccine and a third booster dose with viral vector and Mrna COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of BBIBP-CorV vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.